After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it has found a ...

The year kicked off with a flurry of dealmaking at the J.P. Morgan Healthcare Conference in January, and the pace of news ...

Clinical trials in 2025 will be beset by rising costs and uncertain regulations while also benefiting from new technologies ...

The FDA has granted a groundbreaking approval to Humacyte for its off-the-shelf, bioengineered blood vessel implant, designed ...

A deal with Shanghai Jemincare Pharmaceutical has filled the hole. Rapt is paying $35 million upfront, plus up to $672.5 ...

Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss ...

Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according ...

Fierce Biotech is taking the opportunity to reflect on trends emerging from 2024’s reporting. | For the end of this year, ...

Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...

With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a ...